Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Abliva's CEO to BioStock: "One step closer to a marketed medicine"

Abliva

Abliva has reported positive interim analysis results for the potentially registrational FALCON study, assessing KL1333 in patients with primary mitochondrial disease. While validating the study design and confirming KL1333's strong safety profile, it also triggers a convertible loan conversion, providing Abliva with proceeds of 42 million SEK before transaction costs.
- The interim analysis is an important de-risking event for the program, says Ellen K. Donelly, CEO of Abliva.

Read the full interview with Ellen K. Donelly at biostock.se:

https://www.biostock.se/en/2024/07/ablivas-ceo-one-step-closer-to-a-marketed-medicine/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.